ICU Medical (NASDAQ:ICUI) Price Target Raised to $198.00 at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price objective upped by KeyCorp from $147.00 to $198.00 in a research report released on Tuesday, Benzinga reports. KeyCorp currently has an overweight rating on the medical instruments supplier’s stock.

A number of other research analysts also recently weighed in on ICUI. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an outperform rating in a research report on Thursday, September 12th. Needham & Company LLC reissued a hold rating on shares of ICU Medical in a report on Thursday, October 10th. StockNews.com raised ICU Medical from a hold rating to a buy rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on ICU Medical in a research report on Monday. They set a hold rating and a $183.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $170.25.

ICU Medical Trading Down 0.4 %

Shares of NASDAQ ICUI opened at $179.50 on Tuesday. The company has a market cap of $4.37 billion, a PE ratio of -73.27 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm’s 50 day moving average price is $167.70 and its 200-day moving average price is $130.83. ICU Medical has a 52-week low of $78.28 and a 52-week high of $188.53.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 EPS. On average, equities research analysts expect that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the transaction, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock worth $6,679,322 in the last three months. Corporate insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in ICU Medical by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after buying an additional 55,588 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares during the last quarter. Bank of New York Mellon Corp grew its stake in ICU Medical by 11.5% during the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock valued at $25,710,000 after acquiring an additional 22,310 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in ICU Medical by 9.3% in the 2nd quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock valued at $25,627,000 after acquiring an additional 18,301 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.